Device Trial Radar · NCT07671950
Neuropathic Dental Pain & DBS
Last checked: Nov 19, 2026Latest source record: Jun 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
5
Planned (sponsor's estimate)
Start
Jan 1, 2026
Primary completion
Jan 1, 2027
Study completion Jan 1, 2028
Sponsor
- Lead sponsor
- University of British ColumbiaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jun 26, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Double (participant, care provider)
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 19 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This prospective observational study will evaluate pain outcomes in patients with neuropathic dental pain (Atypical Odontalgia/Phantom Tooth Pain) who undergo directional deep brain stimulation (DBS). Participants will complete validated pain, disability, quality-of-life, and mood assessments before surgery and following DBS programming. Directional stimulation will be applied to different thalamic targets to determine whether specific stimulation settings are associated with greater pain relief. The study aims to characterize changes in pain and quality of life following DBS and to identify the stimulation target associated with the greatest reduction in neuropathic dental pain.
Conditions
- Dental Neuralgia
- Neuropathic Dental Pain
Interventions
Directional Deep Brain StimulationDevice
Participants will receive standard-of-care directional deep brain stimulation (DBS) using an implanted DBS system. Stimulation will be delivered using ring-mode stimulation, directional stimulation toward the ventral posteromedial nucleus (VPM), anterior pulvinar (aPu), or centromedian nucleus (CM), or with stimulation turned off. Participants will undergo each stimulation condition in a randomized sequence.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pain Severity Measured by Visual Analogue Scale (VAS)Time frame: Baseline (pre-operative); after each 2-week stimulation period during the 10-week post-activation programming phase; and 3 months after completion of the randomized stimulation period.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Vancouver General Hospital
Vancouver, British Columbia, Canada · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.